Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.
Pierfranco Conte, MD
Advertisement
Articles by Pierfranco Conte, MD
Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5